openPR Logo
Press release

HER2-Negative Breast Cancer Treatment Market is Expecting Worldwide Growth by 2017 – 2025

08-03-2017 02:38 PM CET | Health & Medicine

Press release from: Persistence Market Research

HER2-Negative Breast Cancer Treatment Market is Expecting

Group of diseases that tend to mutate the cells in the body resulting into uncontrolled division of cells forming a mass or lump called as tumor. Cancer is generally named after the body part from where the tumor originates. The breast cancer originates in the milk production glands that are present in breast tissues called to be as lobules and also originate in the ducts that are connected to lobules. Cancer that originates in the lobules are known to be lobular carcinoma while which begins in the ducts is ductal carcinoma. According to the report published by ASCO (American Society of Clinical Oncology) in 2014, ductal carcinomas contribute to about 75% of all breast cancers. The breast cancer that spreads beyond the ducts or lobules is known to be infiltrating ductal or invasive carcinoma. For invasive cancer, a hospital laboratory test is carried out, wherein HER2 levels are measured particularly, in a sample of breast tissue obtained from a biopsy or surgery. HER2 is also known to be as ERBB2 which is Erb-B2 receptor tyrosine kinase 2. HER2 or ERBB2, is human epidermal growth factor receptor 2 which plays an important role in view of breast cancer. HER2 or ERBB2 gene is responsible for coding HER2 or ERBB2 proteins which are the receptors on the breast. Three common test employed to test for HER2 levels are chromogenic in situ hybridization (CISH), immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH). Depending on the levels of HER2 or ERBB2 in the laboratory test breast cancer is classified as HER2 or ERBB2 positive or HER2 negative breast cancer. In HER2 or ERBB2 receptors in a normal breast maintains growth, division and repairing while in HER2 or ERBB2 positive breast cancer over-expression of HER2 or ERBB2 is seen. In case of HER2 negative breast cancer the levels of HER2 protein is in normal. About 80% of all breast cancers in the U.S are diagnosed as HER2 negative breast cancer, as reported by ASCO (American Society of Clinical Oncology) in a clinical practice guidelines update published for HER2 negative breast cancer in 2014. HER2-negative breast cancer is most common among patients with metastatic breast cancer.

Request to View Tables of Content @ http://www.persistencemarketresearch.com/toc/14566

The treatment for HER2 negative breast cancer includes chemotherapy, radiation, surgery and hormonal or endocrine therapy. Hormonal or endocrine therapy is generally an adjunct therapy given to patients after surgery, chemotherapy or radiation therapy. For treatment of breast cancer receptor testing plays an important role for deciding the treatment for the patient. HER2 negative breast cancer can be ER (Estrogen Receptor) positive if it is tested positive for estrogen receptors; PR (Progesterone Receptor) positive if it is tested positive for progesterone receptor; while breast cancer can be TNBC (Triple Negative Breast Cancer) if there is absence of all three receptors i.e. HER2 or ERBB2, estrogen and progesterone. Generally hormonal therapy is employed for HER2 negative breast cancer. Hormonal therapy works on two basic wherein hormonal drugs or medications that brings down the estrogen level in body or the growth and function of breast cells supported estrogen is blocked. Thus, hormonal therapy is helpful only if the breast cancer cells have hormone receptors that can be targeted in the therapy. But in cases such as TNBC (Triple Negative Breast Cancer) wherein the breast cancer cells are negative for estrogen, progesterone as well as for HER2 (human epidermal growth factor receptor 2), the hormonal therapy is of no use for treatment.

The driver for HER2 negative breast cancer treatment market is the high incidence and growing prevalence of breast cancer in women worldwide. Also there are many drugs in pipeline for the treatment of HER2 negative breast cancer and for treatment of breast cancer in general. While the restraints in HER2 negative breast cancer treatment market is the side effects of treatment such as chemotherapy; there is a threat of reoccurrence of the tumors in majority of treatments; and treatment of cancer requires few or more treatments together which is stressful and expensive for the patient.

The global market for HER2 negative treatment market is segmented on basis of treatment type, and geography:

Segmentation by Treatment type
Chemotherapy
Surgery
Radiation
Hormonal therapy/endocrine therapy
Selective estrogen-receptor response modulators (SERMs)
Estrogen-receptor downregulators (ERDs)
Aromatase inhibitors
Luteinizing hormone-releasing hormone agents (LHRHs)

On basis of treatment type the HER2 negative breast cancer treatment market is segmented into chemotherapy, radiation, surgery and hormonal therapy.

On the basis of regional presence, global HER2 negative breast cancer treatment market is segmented into five key regions viz. North America (NA), Latin America (LA), Europe, Asia Pacific (APAC), and Middle East & Africa (MEA). Some of the major players in global HER2 negative breast cancer treatment market are Array BioPharma, AstraZeneca plc., CELGENE CORPORATION, Eli Lilly and Company, Novartis AG, AbbVie Inc., Merck & Co., Inc., Pfizer Inc., etc.

To view complete report @http://www.persistencemarketresearch.com/market-research/her2-negative-breast-cancer-treatment-market.asp

About Us 
Persistence Market Research (PMR) is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs.
 PMR stands committed to bringing more accuracy and speed to clients’ business decisions. From ready-to-purchase market research reports to customized research solutions, PMR’s engagement models are highly flexible without compromising on its deep-seated research values.

Contact
Persistence Market Research Pvt. Ltd
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
media@persistencemarketresearch.com
Web:www.persistencemarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release HER2-Negative Breast Cancer Treatment Market is Expecting Worldwide Growth by 2017 – 2025 here

News-ID: 654760 • Views:

More Releases from Persistence Market Research

Plastic Liner Market to Reach US$ 6.67 Bn by 2030, Expanding at 4.7% CAGR - Persistence Market Research
Plastic Liner Market to Reach US$ 6.67 Bn by 2030, Expanding at 4.7% CAGR - Pers …
➤ Overview of the Market The global plastic liner market has gained steady traction across multiple industries due to its cost-effectiveness, versatility, and protective characteristics. Plastic liners are widely used in agriculture, mining, construction, waste management, and packaging industries, where they serve as an essential barrier to prevent leakage, contamination, and material loss. These liners are manufactured using materials such as polyethylene (PE), polypropylene (PP), and PVC, offering superior resistance to
Returnable Plastic Crate Market to Reach US$ 2,665.1 Million by 2030 Fueled by Sustainability and Supply Chain Efficiency
Returnable Plastic Crate Market to Reach US$ 2,665.1 Million by 2030 Fueled by S …
➤ Overview of the Market The global returnable plastic crate market is gaining momentum as industries seek cost-effective and sustainable packaging solutions. These crates are widely used for transporting and storing perishable goods, beverages, pharmaceuticals, and industrial products due to their durability, stackability, and reusability. The shift from single-use packaging to eco-friendly alternatives has accelerated the adoption of returnable plastic crates across sectors. The market, valued at US$ 1,820.0 million in
US Thermal Power Market Expected to Reach US$ 251.9 Mn by 2031 with 2.4% CAGR Growth - Persistence Market Research
US Thermal Power Market Expected to Reach US$ 251.9 Mn by 2031 with 2.4% CAGR Gr …
➤Overview of the Market The US thermal power market plays a crucial role in the nation's energy mix, serving as a stable and reliable source of electricity despite the rise of renewables. Thermal power plants in the US rely primarily on coal, natural gas, and oil to generate electricity, with natural gas emerging as the dominant fuel source due to its affordability, efficiency, and lower carbon footprint compared to coal. According
Europe Medical Plastic Market to Reach US$ 17 Bn by 2032 Driven by Rising Healthcare Demand
Europe Medical Plastic Market to Reach US$ 17 Bn by 2032 Driven by Rising Health …
➤Overview of the Market The Europe medical plastic market is undergoing robust growth, fueled by increasing demand for lightweight, durable, and cost-effective materials in the healthcare sector. Medical plastics are widely used in devices, surgical instruments, diagnostic tools, implants, and packaging due to their high biocompatibility, versatility, and resistance to sterilization methods. With healthcare systems across Europe investing heavily in modernization and patient safety, the adoption of medical-grade plastics has gained

All 5 Releases


More Releases for HER2

Evolving Market Trends In The HER2-Positive Breast Cancer Industry: Innovative T …
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics. What Is the Expected HER2-Positive Breast Cancer Market Size During the Forecast Period? Over the past few years, there has been a noteworthy expansion in the HER2-positive breast cancer market. The market, which is projected to increase from $10.21 billion in 2024 to $10.96 billion in the following year, predicts a compound annual growth
HER2 Inhibitors: Advancing Breast Cancer Treatments
"The Business Research Company recently released a comprehensive report on the Global HER2 Inhibitors Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry. Ready to Dive into Something Exciting? Get Your Free Exclusive Sample
HER2 Positive Breast Cancer Pipeline Drugs 2024
DelveInsight's, "HER2 Positive Breast Cancer Pipeline Insight 2024" report provides comprehensive insights about 60+ companies and 65+ pipeline drugs in HER2 Positive Breast Cancer pipeline landscape. It covers the HER2 Positive Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2 Positive Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in
HER2 Inhibitors: Targeted Therapies Transforming Cancer Treatment
HER2 inhibitors market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 9% in the above mentioned forecast period. Global HER2 Inhibitors Market Scope and Market Size The HER2 inhibitors market is segmented on the basis of treatment, application, end-users and distribution channel. The growth amongst these segments will help you analyze
ADC Drugs For HER2 Positive Breast Cancer
According to the latest data, breast cancer has overtaken lung cancer to become the most common cancer among women, and the death rate is the second highest among female tumors, seriously affecting the physical and mental health of women around the world. Patients with abnormal expression of human epidermal growth factor receptor (HER2) account for 15%-20% of all breast cancers, which is highly invasive and has poor prognosis. Although more drug
HER2 negative Breast Cancer Pipeline involves 85+ key companies continuously wor …
DelveInsight's HER2 negative Breast Cancer Pipeline Insight 2022 report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the HER2 negative Breast Cancer pipeline domain. Some of the essential takeaways from the HER2 negative Breast Cancer Pipeline report: • DelveInsight's HER2 negative Breast Cancer Pipeline analysis depicts a robust space with